uniQure N.V.

uniQure announced additional data from its Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease. The 48-month data showed continued slowing of disease progression, with TFC demonstrating 61% slowing (p=0.008), though cUHDRS did not reach statistical significance (p=0.144). The 36-month analysis, including more patients, showed substantial treatment effects with 80% slowing in cUHDRS (p=0.005) and 67% in TFC (p=0.011). The drug was generally well-tolerated, with manageable safety.

uniQure N.V. reported a net loss of $81.1 million for the second quarter of 2026, an increase from $37.7 million in the same period last year, with total revenues rising to $5.8 million. The company successfully completed a follow-on public offering in June 2026, generating net proceeds of $242.7 million, significantly boosting its cash and cash equivalents to $413.0 million. Additionally, uniQure amended its loan facility with Hercules Capital in July 2026, extending the availability of a $100.0 million term loan tranche.

uniQure N.V. reported a net loss of $81.1 million for Q2 2026, compared to $37.7 million in Q2 2025, on revenue of $5.8 million. The company announced that its Biologics License Application (BLA) for AMT-130 for Huntington’s disease remains on track for Q3 2026, following FDA alignment on the accelerated approval pathway. uniQure also strengthened its financial position with a $259 million follow-on offering, extending its cash runway into 2030. Early biological signals were observed for AMT-260 in epilepsy, while dosing for AMT-191 for Fabry disease was paused due to liver enzyme elevations.

uniQure reported its second-quarter 2026 financial results, alongside significant progress in its gene therapy pipeline. The company remains on track for U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease in the third quarter of 2026, with four-year data expected in September. Financially, uniQure strengthened its position with a $259 million follow-on offering, extending its cash runway into 2030. While Q2 2026 revenue increased to $5.8 million, the net loss widened to $81.1 million. Clinical updates included early positive signals for AMT-260 in epilepsy, but AMT-191 for Fabry disease saw dosing paused due to dose-limiting toxicities.

uniQure N.V. announced it will report its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Following the release, management will host a conference call at 8:30 a.m. ET to discuss the results. The event will be accessible via webcast on the company's investor relations website, with a replay available for 90 days.

uniQure N.V. announced the closing of its previously announced underwritten public offering, raising approximately $259 million in aggregate gross proceeds. The offering included 5,686,813 ordinary shares sold at $45.50 per share, with underwriters fully exercising their option to purchase additional shares. The company intends to use the net proceeds to fund commercialization activities for AMT-130, develop other clinical product candidates, pursue business development, and for general corporate purposes.

uniQure N.V. announced the pricing of an upsized underwritten public offering of 4,945,055 ordinary shares at $45.50 per share. The underwriters fully exercised their option to purchase an additional 741,758 ordinary shares. The company expects to receive approximately $242.7 million in net proceeds from the offering, which is anticipated to close around June 25, 2026.

uniQure N.V. announced the pricing of its underwritten public offering of 4,945,055 ordinary shares at $45.50 per share. The offering is expected to generate approximately $225 million in gross proceeds for the company. Underwriters also have an option to purchase up to 741,758 additional shares, with the closing anticipated around June 25, 2026.

uniQure N.V. announced preliminary six-month follow-up data from the first, low-dose cohort of its Phase I/IIa clinical trial for AMT-260, a gene therapy for refractory mesial temporal lobe epilepsy. Three of six patients achieved significant seizure reductions ranging from 79% to 100%, while the other three showed variable changes. The treatment was generally well-tolerated with no serious adverse events reported, and all adverse events were mild or moderate. The company is continuing enrollment for a higher dose cohort and expects to present updated results in the first half of 2027.

uniQure N.V. announced initial six-month follow-up data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy (MTLE). Three of six patients in the low-dose cohort achieved significant reductions in disabling seizures, ranging from 79% to 100% decline from baseline. The investigational gene therapy was generally well-tolerated with no serious adverse events reported, and enrollment is continuing for a higher dose cohort, with updated results anticipated in the first half of 2027.